Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
| Image |  |
|---|---|
| Description | scientific article published on 02 July 2012 |
| Author/s |
author: Ana Ruiz-Garcia Maciej Krzakowski Michael J. Boyer Fiona Blackhall |
| Publication date | July 2, 2012 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |